Supernus Pharmaceuticals reported $1.17M in Interest Expense on Debt for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US USD 66M 75M
Ani Pharmaceuticals ANIP:US USD 7.51M 242K
Aurora Cannabis Inc ACB:CN CAD 10.26M 308K
Bristol Myers Squibb BMY:US USD 294M 5M
Canopy Growth Corp WEED:CN CAD 33.29M 2.82M
Endo International Ordinary Shares ENDP:US USD 74.93M 65M
Marinus Pharmaceuticals MRNS:US USD 3.69M 1.06M
Pacira Pharmaceuticals PCRX:US USD 11.04M 1.18M
Pfizer PFE:US USD 313M 2M
Revance Therapeutics RVNC:US USD 3.75M 3.16M
Supernus Pharmaceuticals SUPN:US USD 1.17M 8K
Teva Pharmaceutical Industries TEVA:US USD 237M 7M
United Therapeutics UTHR:US USD 12.3M 3.1M
Xeris Pharmaceuticals Inc XERS:US USD 4.37M 378K